Oramed Pharmaceuticals Inc (ORMP)vsVertex Pharmaceuticals Inc (VRTX)
ORMP
Oramed Pharmaceuticals Inc
$3.50
+2.34%
HEALTHCARE · Cap: $141.46M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 599965% more annual revenue ($12.00B vs $2.00M). VRTX leads profitability with a 32.9% profit margin vs 21.9%. ORMP trades at a lower P/E of 3.5x. VRTX earns a higher WallStSmart Score of 66/100 (B-).
ORMP
Hold49
out of 100
Grade: D+
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+93.1%
Fair Value
$46.80
Current Price
$3.50
$43.30 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Earnings expanding 40.9% YoY
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 100.0%
Negative free cash flow — burning cash
Operating margin of -6.5%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ORMP
The strongest argument for ORMP centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 21.9% and operating margin at -6.5%.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : ORMP
The primary concerns for ORMP are Market Cap, Revenue Growth, Free Cash Flow.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ORMP profiles as a declining stock while VRTX is a mature play — different risk/reward profiles.
ORMP carries more volatility with a beta of 1.28 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 49/100), backed by strong 32.9% margins. ORMP offers better value entry with a 93.1% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Oramed Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?